Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
12.67
+0.35 (+2.84%)
Streaming Delayed Price
Updated: 1:47 PM EDT, Sep 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Today 9:20 EDT
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Receives USD$2.6 Million Tax Rebate Payment
September 01, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Receives USD$2.6 Million Tax Rebate Payment
September 01, 2026
Lexaria’s 2025 Australian human study results in a USD$2.6 million cash rebate
Via
TheNewswire.com
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2
August 24, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Enters a Material Transfer Agreement With PegBio
August 13, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Announces Effective Date for Reverse Stock Split
July 30, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Updates Business Development
July 06, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
June 25, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
June 23, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
June 17, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
June 09, 2026
Via
ACCESS Newswire
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
June 03, 2026
Via
ACCESS Newswire
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
May 19, 2026
Via
ACCESS Newswire
Lexaria Bioscience Releases Second Episode of Investor Video Series
May 07, 2026
Via
ACCESS Newswire
Lexaria Updates Progress on Human Study #7
May 05, 2026
Via
ACCESS Newswire
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
May 01, 2026
Via
ACCESS Newswire
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
April 29, 2026
Via
ACCESS Newswire
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
April 23, 2026
Via
ACCESS Newswire
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
April 21, 2026
Via
ACCESS Newswire
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
April 15, 2026
Via
ACCESS Newswire
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
April 07, 2026
Via
ACCESS Newswire
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
April 07, 2026
The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects
Via
TheNewswire.com
Lexaria to Begin New Human Clinical Study in GLP-1
April 01, 2026
Via
ACCESS Newswire
Lexaria's Robust Patent Portfolio Continues to Grow
March 26, 2026
Via
ACCESS Newswire
Lexaria's Oral GLP-1 Drug Strategy Validated by Industry
March 24, 2026
Via
ACCESS Newswire
Lexaria Announces New R&D Plans for 2026
March 04, 2026
Via
ACCESS Newswire
Lexaria Announces Positive Final Results From Human Pilot Study #5
February 05, 2026
Via
ACCESS Newswire
Lexaria Awarded Six Additional Patents
January 22, 2026
Lexaria now has 60 patents granted around much of the world
Via
TheNewswire.com
Topics
Intellectual Property
Lexaria Awarded Six Additional Patents
January 22, 2026
Via
ACCESS Newswire
THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point
January 21, 2026
ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC.
From
USA News Group
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
